CML
News
Newer blood cancer drugs may not improve OS, QOL
A study of cancer drugs approved by the European Commission from 2009 to 2013 showed that few hematology drugs were known to provide a benefit in...
News
How Abl ‘shape-shifts’ in drug-resistant CML
Researchers say they have determined how the structure of Abl kinase regulates its activity, enabling the enzyme to switch itself on and off. The...
News
Drugs could improve treatment of CML
Preclinical research suggests 2 drugs already approved for use in the US may improve upon tyrosine kinase inhibitor (TKI) therapy in patients with...
News
Antibiotic could help treat CML
The antibiotic tigecycline may enhance the treatment of chronic myeloid leukemia (CML), according to research published in Nature Medicine. ...
News
CHMP recommends approval of generic imatinib
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for...
News
CHMP recommends approval of nilotinib for kids
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the authorized use for nilotinib (...
News
Report details progress, obstacles in cancer research and care
Deaths from cancer are on the decline in the US, but new cases of cancer are on the rise, according to the 7th annual American Association for...
News
TKI granted priority review for newly diagnosed CML
The US Food and Drug Administration (FDA) has granted priority review to a supplemental new drug application (sNDA) for the tyrosine kinase...
News
Popular theory of mast cell development is wrong, team says
Stem cell factor (SCF) and KIT signaling are not necessary for early mast cell development, according to research published in Blood. It has been...
From the Journals
TKI dose de-escalation feasible in CML with stable MMR
Tyrosine kinase inhibitor de-escalation is generally safe and may lead to symptom improvement in patients with chronic myeloid leukemia who...
Conference Coverage
De-escalation may improve success of TKI cessation
MADRID—Results of the DESTINY trial suggest that chronic myeloid leukemia (CML) patients may improve their chances of successfully stopping...